The clinical program of CLL is rather heterogeneous, ranging from a reasonably asymptomatic disorder that will even regress spontaneously to the progressive illness that ultimately leads to the patient’s death, so there has usually been exceptional desire in determining the prognosis of individual people. Although a lot of prognostic markers are